07/21/2026
"Adequate provision" is the regulatory provision that has made the 60-second drug commercial possible since 1997, and now the ๐๐๐ ๐ต๐ฎ๐ ๐ป๐ผ๐ ๐ฝ๐ฟ๐ผ๐ฝ๐ผ๐๐ฒ๐ฑ ๐๐ผ ๐ฐ๐ต๐ฎ๐ป๐ด๐ฒ ๐ถ๐.
๐ฅ๐ฒ๐บ๐ผ๐๐ฒ ๐ฎ๐ฑ๐ฒ๐พ๐๐ฎ๐๐ฒ ๐ฝ๐ฟ๐ผ๐๐ถ๐๐ถ๐ผ๐ป, and branded TV ads would need to disclose the full approved label on-air, effectively making the format unworkable.
A few developments worth noting:
- The FDA has stated its underlying intent is to ๐ฒ๐ป๐ฑ ๐ฏ๐ฟ๐ฎ๐ป๐ฑ๐ฒ๐ฑ ๐ง๐ฉ ๐ฎ๐ฑ๐๐ฒ๐ฟ๐๐ถ๐๐ถ๐ป๐ด in its current form
- The rule in question has stood since 1969, ๐ฑ๐ณ ๐๐ฒ๐ฎ๐ฟ๐ ๐ผ๐ณ ๐ฟ๐ฒ๐ด๐๐น๐ฎ๐๐ผ๐ฟ๐ ๐ฝ๐ฟ๐ฒ๐ฐ๐ฒ๐ฑ๐ฒ๐ป๐
- The ๐ณ๐ผ๐ฟ๐บ๐ฒ๐ฟ ๐๐๐ ๐๐ผ๐บ๐บ๐ถ๐๐๐ถ๐ผ๐ป๐ฒ๐ฟ defended branded ads on First Amendment grounds at DTC National in April 2026. He was forced out weeks later
- A formal rule change could be proposed as early as ๐บ๐ถ๐ฑ-๐ฎ๐ฌ๐ฎ๐ณ
Legal precedent on commercial free speech makes this unlikely to survive a court challenge. But the disruption to marketers, agencies, and media partners while it moves through litigation could be significant.
If you work in DTC, on the manufacturer side or as an agency, point-of-care, or media partner, this is worth a close read.
๐๐๐น๐น ๐ฎ๐ป๐ฎ๐น๐๐๐ถ๐: https://www.dtcperspectives.com/tv-ad-ban-a-reality/
We'll be examining this issue in depth with webinars and content throughout the year and at the ๐๐ง๐ ๐ก๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น (๐๐๐ป๐ฒ ๐ญ-๐ฏ, ๐ฎ๐ฌ๐ฎ๐ณ, ๐๐ผ๐๐๐ผ๐ป), where marketers get direct access to this analysis and agencies and vendors get face time with the people making these decisions.
